Trial Search Results
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Stanford is currently accepting patients for this trial.
Collaborator: National Cancer Institute (NCI)
- Procedure: Dynamic contrast-enhanced ultrasound imaging
- Device: Optical Tracking Device
- Device: Electromagnetic Tracking Device
- Drug: Perflutren
- Provides written Informed Consent and is willing to comply with protocol requirements.
- Has at least 1 focal lesion in liver or kidney
- Patient may be (i) in the process of receiving treatment (1 scan session), (ii) never
treated (3 scan sessions) or (iii) changing treatment regimen/ type and/or receiving a
new form of treatment and/or has been on a treatment break ('holiday')(3 scan session)
- Is at least18 years of age.
- Is determined by the Investigator that the subject is clinically unsuitable for the
- Known right to left cardiac shunt, bidirectional or transient.
- Hypersensitivity to perflutren.
- Hypersenstivity to the contrast agent Definity.
- Pregnant and lactating women
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study